Clinical study on Shuxuening"Equation missing" combined with antipsychotics in treating chronic schizophreniacombined with antipsychotics in treating chronic schizophrenia

Abstract

100083) ABSTRAOTObjective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN). Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control group in a double-blind research. SXN was given to the SXN group and placebo to the control group, and patients of both groups went on receiving the previous antipsychotic treatment. Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS) and Treatment Emergent Symptoms Scale (TESS) were used to assess the effects of treatment and side effects of the drug. The evaluation was done before and during the 2nd, 4th, 6th, 10th and 12 th weeks in the course of treatment. Results: SXN was effective by BPRS evaluation (P < 0.05), and even the more effective to negative symptoms than positive symptoms by SANS evaluation (P<0.05). It was safe and with little side effect. In addition, it was found that the incipience of SXN's efficacy was somehow related with the course of disease and the daily dosage used. Conclusion: SXN is worthy of further study n the treatment of chronic schizophrenia.

Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment

“…Although NAC has shown positive results in reducing psychotic symptoms, more appropriate stratification of patients by baseline therapy and clinical diagnosis will be needed to compare the effects of antioxidant compounds and their ability to modulate neurobiological outcomes [ 294 , 297 , 298 , 301 ].…”

“…The efficacy of Ginkgo biloba was evaluated in RCTs conducted on patients diagnosed with schizophrenia and showed to significantly decrease SANS and Scale for the Assessment of Positive Symptoms (SAPS) scores when added to haloperidol and administered at a dose of 360 mg/day [ 300 ]. In chronic schizophrenia, the administration of Ginkgo biloba was effective in ameliorating brief psychiatric rating scale (BPRS) and SANS scores compared to the placebo [ 301 , 302 ].…”